{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:25:44Z","timestamp":1791429944572,"version":"4.3.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Parkinson's disease is a neurodegenerative disorder that is characterized by a degeneration of the dopaminergic system. Dopamine transporter (DAT) positron emission tomography (PET) imaging has emerged as a powerful and non-invasive method to quantify dopaminergic function in the living brain. The PET radioligand, [\n                      <jats:sup>18<\/jats:sup>\n                      F]FE-PE2I, a cocaine chemical derivative, has shown promising properties for in vivo PET imaging of DAT, including high affinity and selectivity for DAT, excellent brain permeability, and favorable metabolism. The aim of the current study was to scale up the production of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FE-PE2I to fulfil the increasing clinical demand for this tracer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thus, a fully automated and GMP-compliant production procedure has been developed using a commercially available radiosynthesis module GE TRACERLab FX2 N. [\n                      <jats:sup>18<\/jats:sup>\n                      F]FE-PE2I was produced with a radiochemical yield of 39\u2009\u00b1\u20098% (n\u2009=\u20094, relative [\n                      <jats:sup>18<\/jats:sup>\n                      F]F\n                      <jats:sup>\u2212<\/jats:sup>\n                      delivered to the module). The synthesis time was 70\u00a0min, and the molar activity was 925.3\u2009\u00b1\u2009763\u00a0GBq\/\u00b5mol (250\u2009\u00b1\u200920\u00a0Ci\/\u00b5mol). The produced [\n                      <jats:sup>18<\/jats:sup>\n                      F]FE-PE2I was stable over 6\u00a0h at room temperature.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The protocol reliably provides a sterile and pyrogen\u2013free GMP-compliant product.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-024-00269-9","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T08:02:02Z","timestamp":1714636922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GMP production of [18F]FE-PE2I on a TRACERLab FX2 N synthesis module, a radiotracer for in vivo PET imaging of the dopamine transport"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7004-3565","authenticated-orcid":false,"given":"M\u00e9lodie","family":"Ferrat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M.","family":"Moein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cananau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetyana","family":"Tegnebratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klas","family":"Bratteby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Sam\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy A.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"issue":"601","key":"269_CR1","first-page":"1","volume":"14","author":"K Bratteby","year":"2021","unstructured":"Bratteby K, Denhol CL, Lehel S, Petersen IN, Madsen J, Erlandsson M, Ohlsson T, Herth MM, Gillings N. Fully automated GMP-compliant synthesis of [18F]FE-PE2I. Pharmaceuticals. 2021;14(601):1\u201317.","journal-title":"Pharmaceuticals"},{"key":"269_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00259-009-1267-x","volume":"37","author":"J Darcourt","year":"2010","unstructured":"Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu \u00d6L, N\u00e5gren K, Nobili F, Walker Z, Van Leare K. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Med Mol Imaging. 2010;37:443\u201350.","journal-title":"Eur J Med Mol Imaging"},{"issue":"5","key":"269_CR3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2967\/jnumed.114.152421","volume":"56","author":"P Fazio","year":"2015","unstructured":"Fazio P, Svenningsson P, Forsberg P, J\u00f6nsson EG, Amini N, Nakao R, Nag S, Halldin C, Farde L, Varrone A. Quantitative analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2\u03b2-carbofluoroethoxy-3\u03b2-(4\u2032-methyl-phenyl) nortropane binding to the dopamine transporter in Parkinson disease. J Nucl Med. 2015;56(5):714\u201320. https:\/\/doi.org\/10.2967\/jnumed.114.152421.","journal-title":"J Nucl Med"},{"key":"269_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0969-8051(99)00080-3","volume":"27","author":"MM Goodman","year":"2000","unstructured":"Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, Votaw J, Ely TD, Lambert P, Owens MJ, Camp VM, Malveaux E, Hoffman JM. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol. 2000;27:1\u201312.","journal-title":"Nucl Med Biol"},{"key":"269_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/(SICI)1098-2396(199604)22:4<386::AID-SYN10>3.0.CO;2-W","volume":"22","author":"C Halldin","year":"1996","unstructured":"Halldin C, Farde L, Lundkvist C, Ginovart N, Nakashima Y, Karlsson P, Swahn C-G. [11C]\u03b2-CIT-FE, a radioligand for quantification of the dopamine transporter in the living brain using positron emission tomography. SYNAPSE. 1996;22:386\u201390.","journal-title":"SYNAPSE"},{"key":"269_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1007\/s00259-003-1212-3","volume":"30","author":"C Halldin","year":"2003","unstructured":"Halldin C, Erixon-Lindroth N, Pauli S, Chou Y-H, Okubo Y, Karlsson P, Lundkvist C, Olsson H, Guilloteau D, Emond P, Farde L. [11C]PE2I, a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Med Mol Imaging. 2003;30:1220\u201330.","journal-title":"Eur J Med Mol Imaging"},{"key":"269_CR7","unstructured":"Hermes Medical Solution, Sweden software: https:\/\/www.hermesmedical.com\/our-software\/"},{"key":"269_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13550-018-0450-0","volume":"8","author":"S Jakobson Mo","year":"2018","unstructured":"Jakobson Mo S, Axelsson J, Jonasson L, \u00d6gren MJ, \u00d6gren M, Varrone A, Eriksson A, B\u00e4ckstr\u00f6m D, af Bjerk\u00e9n S, Linder J, Riklund K. Dopamin transporter imaging with [18F]FE-PE2I PET and [123I]FE-CIT SPECT: a clinical comparison. EJNMMI Res. 2018;8:100\u201313.","journal-title":"EJNMMI Res"},{"key":"269_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/(SICI)1098-2396(199803)28:3<244::AID-SYN7>3.0.CO;2-A","volume":"28","author":"A Laakso","year":"1998","unstructured":"Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Hietala J. [18F]CFT ([18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: characterization in human subjects. SYNAPSE. 1998;28:244\u201350.","journal-title":"SYNAPSE"},{"issue":"1","key":"269_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13550-022-00930-x","volume":"12","author":"L Marner","year":"2022","unstructured":"Marner L, Korsholm K, Anderberg L, Lonsdale MN, Jensen MR, Br\u00f8dsgaard E, et al. [18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism. EJNMMI Res. 2022;12(1):56.","journal-title":"EJNMMI Res"},{"key":"269_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0969-8051(93)90045-V","volume":"20","author":"L M\u00fcller","year":"1993","unstructured":"M\u00fcller L, Halldin C, Farde L, Karlsson P, Hall H, Swahn C-G, Neumeyer J, Gao Y, Milius R. [11C]\u03b2-CIT, a cocaine analogue. Preparation, autoradiography and perliminary investigation. Nucl Med Biol. 1993;20:249\u201355.","journal-title":"Nucl Med Biol"},{"key":"269_CR12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/cells8080872","volume":"8","author":"G Palermo","year":"2019","unstructured":"Palermo G, Ceravolo R. Molecular imaging of the dopamine transporter. Cells. 2019;8:872\u201388.","journal-title":"Cells"},{"key":"269_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2967\/jnumed.110.077651","volume":"52","author":"T Sasaki","year":"2011","unstructured":"Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, Kodaka F, Fujie S, Takahata K, Nogami T, Suzuki M, Fujiwara H, Takahashi H, Nakao R, Fukumura T, Varrone A, Halldin C, Nishikawa T, Suhara T. Quantification of dopamine transporter in the human brain using PET with 18F-FE-PE2I. J Nucl Med. 2011;52:132\u20139.","journal-title":"J Nucl Med"},{"key":"269_CR14","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1016\/j.bmcl.2009.06.032","volume":"19","author":"M Schou","year":"2009","unstructured":"Schou M, Stieger C, Varrone A, Guilloteau D, Halldin C. Synthesis, radiolabeling and perlimanary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. Bioorg Med Chem Lett. 2009;19:4843\u20135.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"269_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36(1):1\u201312.","journal-title":"Clin Geriatr Med"},{"key":"269_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jlcr.2927","volume":"55","author":"V Stepanov","year":"2012","unstructured":"Stepanov V, Krasikova R, Raus L, Loog O, Hiltunen J, Halldin C. An efficient one-step radiosynthesis of [18F]FE-PE2I, a PET radioligand for imaging of dopamine transporters. J Label Compd Radiopharm. 2012;55:206\u201310.","journal-title":"J Label Compd Radiopharm"},{"key":"269_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2967\/jnumed.109.065656","volume":"51","author":"A Varrone","year":"2010","unstructured":"Varrone A, Halldin C. Molecular imaging of the dopamine transporter. J Nucl Med. 2010;51:1331\u20134.","journal-title":"J Nucl Med"},{"key":"269_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2967\/jnumed.111.089953","volume":"52","author":"A Varrone","year":"2011","unstructured":"Varrone A, Stepanov V, Nakao R, T\u00f3th M, Guly\u00e1s B, Emond P, Bernard Deloye J, Vercouillie J, Stabin MG, Jonsson C, Guilloteau D, Halldin C. Imaging of the striatal and extrastriatal dopamintransporter with 18F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates. J Nucl Med. 2011;52:1313\u201321.","journal-title":"J Nucl Med"},{"key":"269_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2967\/jnumed.111.101626","volume":"53","author":"A Varrone","year":"2012","unstructured":"Varrone A, T\u00f3th M, Steiger C, Takano A, Guilloteau D, Ichise M, Guly\u00e1s B, Halldin C. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. J Nucl Med. 2012;53:1065\u201373.","journal-title":"J Nucl Med"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-024-00269-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-024-00269-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-024-00269-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T08:09:36Z","timestamp":1714637376000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-024-00269-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["269"],"URL":"https:\/\/doi.org\/10.1186\/s41181-024-00269-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4118168\/v1","asserted-by":"object"}]},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No animal- or clinical trials were conducted in this report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval and consent to participate"}},{"value":"The clinical patient data used in the publication have been anonymized and safeguards measures taken to follow the GDPR (General Data Protection Regulation) requirements according to the Karolinska University Hospital\u2019s regulation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}